RTP-801i: Phase I started

Quark began a Phase I trial of RTP-801i to treat wet age-related macular degeneration (AMD). The trial is being funded by PFE which licensed RTP-801i from Quark in 2006 (see BioCentury, Oct. 2, 2006)....